Saturday, November 23, 2019 10:56:00 AM
Conservatively this is $45-$60 company given its potential and how easy and quick this will be FDA approved. They’re funded and they expect a “LARGER PHARMA” to bring GDC-0084 to fruition.
For GDC 0084 to work this well as a monotherapy it will CERTAINLY raise eyebrows of the worlds best experts over the weekend. Look who is presenting the data non other than Prof Wen!!!!
Dana Farber - Harvard Medical - MD Anderson - UCLA - Stephenson Cancer - John Theurer - Genetech
Poster Presenting Author(s)
Patrick Wen
Director, Center For Neuro-Oncology
ACTR-64 - Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 in GBM patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status
Recent KZIA News
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases • PR Newswire (US) • 03/21/2024 12:52:00 PM
- Kazia announces presentation of new data at AACR Annual Meeting • PR Newswire (US) • 03/13/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/21/2024 09:19:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 02:19:28 PM
- Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint • PR Newswire (US) • 02/21/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:41:16 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 11:35:07 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:28 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/05/2024 09:19:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/18/2024 09:30:53 PM
- KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS • PR Newswire (US) • 01/18/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:05:27 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/15/2023 10:26:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2023 01:31:56 PM
- Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering • PR Newswire (US) • 12/05/2023 11:02:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/04/2023 09:05:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/01/2023 01:30:27 PM
- Kazia Therapeutics Announces $2 Million Registered Direct Offering • PR Newswire (US) • 12/01/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 09:19:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 09:02:58 PM
- KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY • PR Newswire (US) • 11/29/2023 12:01:00 PM
- KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING • PR Newswire (US) • 11/21/2023 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 09:39:56 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM